Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28484771 | 0.91 | QDPR (0.39) | QDPR | |
| SCHEMBL20090538 | 0.74 | — | — | |
| SCHEMBL2522575 | 0.73 | QDPR (0.34) | QDPR | |
| SCHEMBL8085794 | 0.70 | — | — | |
| SCHEMBL28742007 | 0.69 | QDPR (0.41) | QDPR | |
| SCHEMBL31718158 | 0.69 | QDPR (0.63) | QDPR | |
| SCHEMBL17034783 | 0.69 | RIPK1 (0.42) | QDPR | |
| SCHEMBL91421 | 0.67 | — | — | |
| SCHEMBL28890444 | 0.66 | QDPR (0.45) | QDPR | |
| SCHEMBL15144402 | 0.65 | QDPR (0.41) | QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116917280-B | Tetrahydronaphthalene compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12435092-B2 | Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| WO-2025128933-A1 | GABA-A RECEPTOR POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250099596-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-03-27 | — | — | US | disclosed |
| EP-4526304-A1 | INHIBITORS OF PARG | 858 Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240352018-A1 | SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2024-10-24 | — | — | US | disclosed |
| EP-3519409-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING HIV INFECTION | GILEAD SCIENCES INC (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | NOVARTIS AG (CH) | 2013-10-03 | — | — | US | disclosed |
| US-8481542-B2 | Pyridazinyl derivatives as smo inhibitors | NOVARTIS AG (CH) | 2013-07-09 | — | — | US | disclosed |
| US-20120302569-A1 | PHENYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | NOVARTIS AG (CH) | 2012-11-15 | — | — | US | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | NOVARTIS AG | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | QDPR 391/4885 |
| US-12435092-B2 | Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG | PARG, PLG, PTGIS | QDPR 178/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | QDPR 687/4885 |
| US-20130261299-A1 | PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS | SMO, SHH, GLI1 | QDPR 1309/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | QDPR 165/4885 |
| US-20250099596-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | CYP51A1, CYP46A1, HSD17B11 | QDPR 229/4885 |
| US-20240352018-A1 | SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG | PARG, PLG, PARN | QDPR 278/4885 |
| US-20100041663-A1 | Organic Compounds as Smo Inhibitors | SMO, GLI1, SHH | QDPR 3109/4885 |
| US-20120289507-A1 | ORGANIC COMPOUNDS AS SMO INHIBITORS | SMO, GLI1, SHH | QDPR 3109/4885 |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | QDPR 2647/4885 |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | QDPR 391/4885 |
| US-20120302569-A1 | PHENYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP9, MMP1, MMP3 | QDPR 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.